RT Journal Article
SR Electronic
T1 Metastatic Lymph Node Station Number Predicts Survival in Small Cell Lung Cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.06.20189191
DO 10.1101/2020.09.06.20189191
A1 Han Zhang
A1 Cong Jiang
A1 Kaiqi Jing
A1 Jing Zhang
A1 Yan Chen
A1 Yuming Zhu
A1 Gening Jiang
A1 Peng Zhang
YR 2020
UL http://medrxiv.org/content/early/2020/09/08/2020.09.06.20189191.abstract
AB Purpose As for pathologic N category, various regrouping strategies have been raised in non-small cell lung cancer (NSCLC) but little was done in small cell lung cancer(SCLC). On the basis of the suggestions discussed in NSCLC, we proposed a novel, metastatic lymph node station number (MNSN) - based pathologic N parameter and compared its efficacy in predicting survival with pN in SCLC.Methods We retrospectively analyzed the patients operated and pathologically diagnosed as SCLC in our hospital between 2009 and 2019. Kaplan–Meier method and Cox regression analysis were used to compare survival between groups defined by pN and MNSN.Results From 2009 to 2019, 566 patients received surgery for SCLC and 530 of them were eligible for subsequent analysis, with a median follow-up time of 21 months. The 5-year overall survival (OS) rates were 58.8%, 38.6%, 27.9% for pN0, pN1, pN2 stages and were 58.8%, 36.8%, 22.1%, 0% for MNSN0, 1-2, 3-5, 6-7 groups, respectively. Analyses of overall and recurrence-free survival (RFS) revealed that pN1 could not be distinguished from pN2 (OS, p = 0.099; RFS, p = 0.254), but the groups in MNSN were well separated from each other (OS, p< 0.001, p = 0.001, p = 0.063; RFS, p< 0.001, p = 0.026, p = 0.01, compared with the former group). When adjusted for sex, age, smoking, tumor purity and T stage, MNSN groups were independent hazard factors for OS and RFS.Conclusions Based on our cohort study, the MNSN-based N parameter might be a better indicator to predict survival than pN in SCLC and worth considering in the definition of N category in the future.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the National Natural Science Foundation of China [Grant No. 81972172], the Shanghai Hospital Development Center [Grant No. SHDC12018122], the Shanghai Science and Technology Committee [Grant No. 19XD1423200], and Programs of Shanghai Pulmonary Hospital [No. fkcx1904].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee Shanghai Pulmonary HospitalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw/processed data required to reproduce these findings cannot be shared at this time as the data also forms part of an ongoing study.